On the one hand, a high level of estrogens may lead to the formation of prolactinomas [47], and on the other hand, PD treatment with L-dopa and other antiparkinsonian drugs such as cabergoline suppress PRL secretion from the pituitary gland and may lead to hypoprolactinemia. The gene discussed is PRL; the disease is Parkinson disease.